Curr Opin Investig Drugs. 2005 Jul;6(7):717-21.

Talnetant GlaxoSmithKline.

Source

Menarini Ricerche SpA, Via Sette Santi 1, 50131, Firenze, Italy. sevangelista@menarini-recherche.it

Abstract

Talnetant (SB-223412) is a selective, orally active NK3 antagonist based on 4-quinolinecarboxamide, and is under development by GlaxoSmithKline (formerly SmithKline Beecham) for the potential treatment of several disorders, including urinary incontinence, irritable bowel syndrome and schizophrenia. By November 2004, the compound had completed phase II trials.

PMID:: 16044668; [PubMed - indexed for MEDLINE]

Publication Types, MeSH Terms, Substances

Publication Types

Review

MeSH Terms

Substances

LinkOut - more resources

Other Literature Sources

Supplemental Content

Save items

Related citations in PubMed

Review TAK-637. Takeda. [Curr Opin Investig Drugs. 2001]
Review TAK-637. Takeda.
Furness JB. Curr Opin Investig Drugs. 2001 Oct; 2(10):1437-40.
Review Tachykinin receptors antagonists: from research to clinic. [Curr Drug Targets. 2006]
Review Tachykinin receptors antagonists: from research to clinic.
Quartara L, Altamura M. Curr Drug Targets. 2006 Aug; 7(8):975-92.
Review Technology evaluation: SB-485232, GlaxoSmithKline. [Curr Opin Mol Ther. 2005]
Review Technology evaluation: SB-485232, GlaxoSmithKline.
Golab J, Stoklosa T. Curr Opin Mol Ther. 2005 Feb; 7(1):85-93.
Asymmetric synthesis of an antagonist of neurokinin receptors: SSR 241586. [J Org Chem. 2011]
Asymmetric synthesis of an antagonist of neurokinin receptors: SSR 241586.
Métro TX, Cochi A, Gomez Pardo D, Cossy J. J Org Chem. 2011 Apr 15; 76(8):2594-602. Epub 2011 Mar 16.
Technology evaluation: mepolizumab, GlaxoSmithKline. [Curr Opin Mol Ther. 2003]
Technology evaluation: mepolizumab, GlaxoSmithKline.
Gnanakumaran G, Babu KS. Curr Opin Mol Ther. 2003 Jun; 5(3):321-5.

See reviews... See all...

Cited by 2 PubMed Central articles

Newer molecules in the treatment of schizophrenia: A clinical update. [Indian J Pharmacol. 2011]
Newer molecules in the treatment of schizophrenia: A clinical update.
Ghosh A, Chakraborty K, Mattoo SK. Indian J Pharmacol. 2011 Apr; 43(2):105-12.
Characterization of RO4583298 as a novel potent, dual antagonist with in vivo activity at tachykinin NK₁ and NK₃ receptors. [Br J Pharmacol. 2011]
Characterization of RO4583298 as a novel potent, dual antagonist with in vivo activity at tachykinin NK₁ and NK₃ receptors.
Malherbe P, Knoflach F, Hernandez MC, Hoffmann T, Schnider P, Porter RH, Wettstein JG, Ballard TM, Spooren W, Steward L. Br J Pharmacol. 2011 Feb; 162(4):929-46.

Related information

Related Citations
Calculated set of PubMed citations closely related to the selected article(s) retrieved using a word weight algorithm. Related articles are displayed in ranked order from most to least relevant, with the “linked from” citation displayed first.
Compound (MeSH Keyword)
PubChem chemical compound records that are classified under the same Medical Subject Headings (MeSH) controlled vocabulary as the current articles.
MedGen
Related information in MedGen
Substance (MeSH Keyword)
PubChem chemical substance (submitted) records that are classified under the same Medical Subject Headings (MeSH) controlled vocabulary as the current articles.
Cited in PMC
Full-text articles in the PubMed Central Database that cite the current articles.

Recent activity

Clear Turn Off Turn On

Talnetant GlaxoSmithKline.
Talnetant GlaxoSmithKline.
Curr Opin Investig Drugs. 2005 Jul ;6(7):717-21.

PubMed

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

PubMed

Result Filters

Display Settings:

Send to: